Alcon News
Print this Article | Send to Colleague
Alcon News
Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business
Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that it has completed its acquisition of Aerie Pharmaceuticals, Inc. This transaction helps bolster Alcon’s presence in the ophthalmic pharmaceutical space with its growing portfolio of commercial products and development pipeline.
“As we welcome the Aerie team to Alcon, we look forward to leveraging our expanding commercial footprint and expertise to bring Rocklatan® and Rhopressa® to even more customers and their patients,” said David Endicott, CEO of Alcon. “Alcon has a rich history in the ophthalmic pharmaceutical space rooted in a deep understanding of Eye Care Professionals. We are excited to add Aerie’s significant technical expertise to Alcon R&D, which enhances our efforts to build a compelling portfolio of ophthalmic pharmaceuticals.”
Through the transaction, Alcon has added the commercial products Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa (netarsudil ophthalmic solution) 0.02%, as well as AR-15512, a Phase 3 product candidate for dry eye disease. Alcon has also acquired a pipeline of ophthalmic pharmaceutical product candidates with the opportunity to leverage Aerie’s existing research and development capabilities.
The transaction complements Alcon’s expansion intothe ophthalmic pharmaceutical space, including acquisitions of the exclusive U.S. commercialization rights for Simbrinza® from Novartis in April 2021 and Eysuvis® and Inveltys® from Kala Pharmaceuticals, Inc. in May 2022.
